Generic Drug Price Inflation Tackled In Congressional Budget Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
A provision in the Bipartisan Budget Act of 2015 will require that generic drug manufacturers pay additional rebates to Medicaid if prices increase faster than inflation, as manufacturers of single-source brands do.
You may also be interested in...
Medicaid Drug Rebates Will Get Closer Scrutiny From CMS, Verma Pledges
CMS Administrator-nominee Seema Verma promises stronger agency oversight of Medicaid drug rebate program in response to question from Sen. Grassley during Senate confirmation hearing.
REMS And Generics: GPhA Needs Legislation, Continues Education
GPhA says congressional action is only remedy after study estimates $5.4 billion in potential savings is lost annually because of brand manufacturers using REMS to prevent generic competition.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.